Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Background
- Estimates of American Cancer Society for 2005
- Gene/environment interactions
- Goals of this presentation
- Biomarkers- from exposure to disease
- Parts of presentation
- Part I: genetic susceptibility of lung cancer risk
- The paradigm
- Polymorphic metabolizing genes in lung cancer
- Methods - case-control study
- Methods - information and analyses
- SNP and lung cancer - MnSOD
- Pyrosequencing for MnSOD polymorphism
- Ala9Val MnSOD polymorphism results
- GSTP1 and early lung carcinoma in women
- Multivariate analysis for GSTP1 polymorphism
- mEH polymorphism and cigarette smoking
- Results of the study
- Lung cancer risk of low mEH and other genotypes
- Putative mechanism
- DNA repair and cancer risk
- Mammalian DNA repair systems
- Genes in DNA repair pathways
- Role of ERCC2 polymorphism
- Model evaluating ERCC2 and smoking
- Role of XRCC1 polymorphism
- Model evaluating XRCC1 and smoking
- Role of ERCC1 polymorphism
- Model evaluating ERCC1 and smoking
- Summary: part I
- Part II: DNA repair and treatment response
- DNA repair polymorphisms and treatment response
- DNA repair polymorphisms and overall survival
- Adjusted hazard ratios
- Kaplan-Meier curves of the ERCC2 polymorphism
- Kaplan-Meier curves of the XRCC1 polymorphism
- Kaplan-Meier curves of the ERCC1 polymorphism
- DNA repair polymorphism and GI toxicity
- ERCC1 polymorphism and GI toxicity
- Vitamin D and survival in early stage NSCLC
- Proposed mechanism for vitamin D and cancer
- Vitamin D is important at treatment initiation
- Patient and tumor characteristics
- Treatment and follow-up characteristics
- Recurrence time
- Overall survival
- Summary: part II
- Where do we go from here?
- Possible future applications
- LCS research team (1)
- LCS research team (2)
- Grant support
Topics Covered
- The influence of host factors on individual susceptibility to tobacco smoke
- The pleiotropic genes that control activation (Phase I) and detoxification (Phase II) of potential carcinogens
- Effects of the metabolism of environmental compounds on the lipophilic properties of a molecule and the introduction of electronegative moieties within the molecule on carcinogenic potential
- Other susceptibility factors related to defects in DNA repair, alterations in tumor suppressor genes and alterations in tumor invasiveness factors
- Polymorphisms in genes and the association of this with lung cancer development
- The role of inherited polymorphisms of genes involved in xenobiotic metabolism, DNA repair and tumor suppression/invasion (alone and in combination) in lung cancer risk, and modification of this risk by environmental factors such as smoking and diet
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Christiani, D. (2007, October 1). Molecular epidemiology of lung cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 7, 2024, from https://doi.org/10.69645/MGML6765.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Christiani has served as a paid expert on behalf of victims (plaintiff) cases against tobacco companies.